Clinical Trial Update: Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 safety and efficacy study of anti-PD1 armored CD19 CAR-T cells in adults with relapsed or refractory diffuse large B-cell lymphoma is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Anti-PD1 Armored CD19 CAR-T Cells

Snippet

Sponsor: Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | Conditions: Diffuse Large B Cell Lymphoma | Phase 1 | Status: RECRUITING